You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. AI-enabled fully automated retinal image-based biomarkers for mild cognitive impairment and neurodegenerative disorders

    SBC: EYENUK, INC.            Topic: NINDS

    AbstractIn this SBIR projectwe present EyeQuantan AI enabled fully automated tool to compute retinal image based biomarkers for mild cognitive impairment and neurodegenerative disordersThe largegrowingand aging population is likely to lead to a dramatic increase in the number of people at risk for dementia and other cognitive disorderswith more thanmillion people expected to be affected byVascular ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Targeting PDGFs for Potential Treatment of Proliferative Vitreoretinopathy

    SBC: APTITUDE MEDICAL SYSTEMS INC            Topic: NEI

    Abstract SignificanceProliferative vitreoretinopathyPVRis a blinding orphan indication that occurs inof patients receiving rhegmatogenous retinal reattachment surgeryand accounts forof all primary surgical failuresPVR is characterized by migration and proliferation of ectopic cells beneath or on the surface of the retinawhich then assemble into a membranecausing retinal traction and detachmentSinc ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Treatment of Chemotherapy-Induced Peripheral Neuropathy via Genetic Repression of Sodium Channels

    SBC: NAVEGA THERAPEUTICS, INC.            Topic: 102

    Project Summary Abstract The goal of this project is to develop a therapeutic product that relieves chemotherapy induced peripheral neuropathyCIPNin a non permanentnon addictive and long lasting manner to improve the quality of life of cancer patientsCurrently more thanmillion Americans andbillion people worldwide suffer from chronic painVoltage gated sodium channels transmit pain signals in nocic ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Biosensor and Eyedrop Bottle Technologies for Glaucoma Adherence Monitoring

    SBC: Toromedes, Inc            Topic: NEI

    Project SummaryNon adherence with prescribed systemic drugs leads to poor outcomes and increases the cost of healthcareGlaucomathe leading cause of irreversible blindnessaffects more thanmillion people worldwideLowering intraocular pressurethe only proven method of delaying both the development and progression of glaucomais typically done with topical administration of eye dropswhich has notorious ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Development of An Oral,Brain/Eye penetrating, Second Generation TTR Stabilizer for The Treatment of Transthyretin Amyloidoses

    SBC: PROTEGO BIOPHARMA, INC.            Topic: NINDS

    The TTR Amyloidoses (ATTR) are rare, progressive, ultimately fatal diseases that compromise the function of multiple organs, causing a wide range of debilitating clinical symptoms. ATTR is caused by the dissociation of the tetrameric transthyretin (TTR) protein, leading to misfolding and aggregation of the released monomers with toxic oligomer formation and subsequent tissue deposition as physiolo ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a biomimetic small molecule therapeutic for neovascular retinal diseases

    SBC: EyeMedix, Inc.            Topic: NEI

    PROJECT SUMMARY / ABSTRACTRetinal diseases, including age-related macular degeneration (AMD) and diabetic retinopathy (DR) are the leading causes of vision loss and blindness in people over 55 years old. According to the NEI, in 2010 nearly 10 million people in the U.S. suffered from some form of these diseases, whose prevalence is expected to increase to 15 million over 20 years.Recently approved ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Peripherally-Restricted Long-Acting Somatostatin Receptor 4 (LA-SSTR4) Agonists for Pain

    SBC: PEPTIDE LOGIC LLC            Topic: NIDA

    PROJECT SUMMARY ABSTRACT The proposed SBIR Phase II program seeks to select a first in classperipherally restrictedand long acting somatostatin receptorLA SSTRagonist clinical candidate for development as a novel non addictive analgesic able to replace opioids for the treatment of moderate to severe chronic painThe program is based on strong scientific evidence showing that activation of periphera ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Pharmacokinetic and toxicology studies of AYX2, a transcription factor decoy, non-opioid, disease modifying drug candidate for the long-term treatment of chronic pain

    SBC: Adynxx, Inc.            Topic: NINDS

    RESEARCH AND RELATED OTHER PROJECT INFORMATIONPROJECT SUMMARYABSTRACTFunding OpportunityPAPI NameMametJulienAs described by the HEAL Initiative Notice NOT NSthere currently exists an urgent unmet need for enhanced pain management in the form of safeeffectivenon opioid pain treatmentsChronic focal neuropathic painwhich includes pain etiologies such as radiculopathy and radiculitisfocal peripheral n ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Supplement to Promote Diversity and Inclusion, Female Scientist

    SBC: NAVEGA THERAPEUTICS, INC.            Topic: NINDS

    Project Summary/Abstract Currently more than 100 million Americans and 1.5 billion people worldwide suffer from chronic pain. This is more than cancer, diabetes, and heart disease combined. Voltage-gated sodium channels are responsible for the transmission of pain signals. Nine genes have been identified, each having unique properties and tissue distribution patterns. Genetic studies have correlat ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Targeting lipid rafts for treatment of migraine

    SBC: RAFT PHARMACEUTICALS LLC            Topic: NINDS

    PROJECT SUMMARY Migraine is a highly prevalent condition with an extraordinarily negative impact on quality of life and represents a heavy socioeconomic burden to the societyprimarily because of decreased working efficiency and workdays lostManagement of migraine has become increasingly pharmacological during recent yearsWhile several therapeutic options existmost of the prophylactic drugs current ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government